ClinicalTrials.gg
CompletedNCT07945262Updated Nov 18, 2026

Antenatal Education and Brochures to Improve Anaemia Awareness and Iron Use in Pregnant Women

An interventional study of Antenatal Education Class and Anaemia Awareness Brochure in Anemia, Iron-Deficiency, Anemia in Pregnancy and Pregnancy, sponsored by Sakarya University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Sakarya University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Jan 2022, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Anemia, Iron-Deficiency with a site in Turkey — none open to participants now, none under way, none of them phase 3. Anemia, Iron-Deficiency · Turkey.

Started
2022
with 3 others
No phase
6 of 13
none open now
Registered
13th of 13
by date

Among the 13 studies in Anemia, Iron-Deficiency with a site in Turkey, this one is one of 4 that started in 2022, is one of 6 with no phase, and was the 13th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

None of the 13 studies in Anemia, Iron-Deficiency with a site in Turkey is open now. The open studies under Anemia, Iron-Deficiency, anywhere →

Who these studies take

Of the 52 Anemia, Iron-Deficiency studies recruiting now, 18 (35%) set no upper age limit and 30 (58%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Anemia, Iron-Deficiency with a site in Turkey as a file.
02

Study summary

Anaemia is common in pregnancy and can cause problems for both the mother and the baby. Iron tablets are an effective treatment, but many pregnant women do not take them regularly. Reasons include forgetfulness, side effects, and limited knowledge about anaemia.

This randomized controlled study evaluated whether giving pregnant women additional education about anaemia, on top of routine prenatal care, improves their awareness of anaemia, their regular use of iron supplements, and their haemoglobin levels.

Pregnant women aged 18 to 45 years, between 16 and 34 weeks of pregnancy and diagnosed with anaemia, were randomly assigned to one of three groups:

Group 1: routine information + an anaemia awareness brochure + an antenatal education class Group 2: routine information + an anaemia awareness brochure only Group 3 (control): routine information only

Anaemia awareness, iron supplement use, and haemoglobin levels were assessed at the start of the study and after 4 weeks. Haemoglobin levels after delivery were also recorded.

The main question of the study was whether haemoglobin levels after 4 weeks differ among the three groups. The study also examined whether education and brochures increase women's knowledge about anaemia and help them take iron supplements more regularly.

03

Conditions studied

  • Anemia, Iron-Deficiency
  • Anemia in Pregnancy
  • Pregnancy

Keywords

  • Antenatal Education
  • Prenatal Care
  • Patient Education Brochure
  • Iron Supplementation
  • Medication Adherence
  • Anaemia Awareness
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 18 to 45 years
  • Gestational age between 16 and 34 weeks
  • Diagnosed with anaemia ( \< 11 g/dL)
  • Prescribed oral iron supplementation
  • Singleton pregnancy
  • Able to read and understand Turkish
  • Agreed to participate and provided written

Exclusion criteria

Exclusion Criteria:

  • Known haemoglobinopathy (e.g., thalassaemia, sickle cell disease) or other haematological disease
  • Chronic systemic disease (e.g., chronic kidney disease, inflammatory bowel disease, )
  • Severe anaemia requiring parenteral iron therapy or blood transfusion
  • Multiple pregnancy
  • Psychiatric disorder or cognitive impairment preventing participation in education
  • Previous participation in a structured antenatal education programme on anaemia
  • Withdrawal of consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    Experimental 1: Brochure + Antenatal Education Class

    Pregnant women with anaemia received routine prenatal information plus an anaemia awareness brochure and a face-to-face antenatal education class. The class and brochure covered the definition, causes, symptoms, maternal and fetal risks, and prevention of anaemia, iron-rich nutrition, and the correct use of oral iron supplements.

    Behavioral: Antenatal Education Class · Behavioral: Anaemia Awareness Brochure · Other: Routine Prenatal Care

  • Experimental
    Experimental 2: Brochure Only

    Pregnant women with anaemia received routine prenatal information plus an anaemia awareness brochure covering anaemia in pregnancy, its risks, iron-rich foods, and the correct use of oral iron supplements. No education class was provided.

    Behavioral: Anaemia Awareness Brochure · Other: Routine Prenatal Care

  • Experimental
    Control: Routine Care

    Pregnant women with anaemia received only routine prenatal information and care as provided in standard practice, without the brochure or education class.

    Other: Routine Prenatal Care

Interventions

  • BehavioralAntenatal Education Class

    A face-to-face group education class for pregnant women with anaemia, delivered in addition to routine prenatal care. The class covered the definition, causes, symptoms, and maternal and fetal risks of anaemia in pregnancy, its prevention, iron-rich nutrition, factors affecting iron absorption, and the correct use of oral iron supplements, including timing, possible side effects, and the importance of daily use. Participants in this arm also received the anaemia awareness brochure.

  • BehavioralAnaemia Awareness Brochure

    A printed brochure prepared by the researchers, given to participants in addition to routine prenatal care. The brochure provided information on anaemia in pregnancy, its risks for mother and baby, iron-rich foods, factors affecting iron absorption, and how to take oral iron supplements correctly and regularly.

  • OtherRoutine Prenatal Care

    Standard routine prenatal information and care provided as usual practice, without additional brochure or education class.

06

What researchers measure

Primary outcomes

  1. Haemoglobin Level at 4 Weeks

    Haemoglobin concentration (g/dL) will be measured by complete blood count at baseline and at the end of week 4. Post-intervention haemoglobin levels will be compared among three groups: Experimental 1 (routine counselling + anaemia awareness brochure + antenatal education class), Experimental 2 (routine counselling + brochure only), and Control (routine counselling only). The comparison will use analysis of covariance (ANCOVA) adjusted for baseline haemoglobin.

    Time frame: Baseline and 4 weeks after enrollment

  2. Change in Anaemia Awareness Score

    Anaemia awareness will be assessed using a structured questionnaire covering the definition, causes, symptoms, maternal and fetal risks, prevention, and iron-rich nutrition. Higher scores indicate greater awareness. Within-group change and between-group differences in post-intervention scores will be evaluated.

    Time frame: Baseline and 4 weeks after enrollment

  3. Adherence to Oral Iron Supplementation

    Adherence to prescribed oral iron supplementation will be assessed by self-report.. The proportion of participants taking iron supplements every day will be compared within and between groups.

    Time frame: Baseline and 4 weeks after enrollment

07

Study locations

1 site
  • SAhttps://tip.sakarya.edu.tr/en
    Sakarya, 541000, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the article (demographic characteristics, haemoglobin values, anaemia awareness scores, and iron supplement use data) will be shared.

Supporting information: Study protocol

Time frame: Data will be available beginning 6 months after publication of the article and ending 5 years after publication.

Access criteria: Data will be shared with researchers who provide a methodologically sound proposal, upon reasonable request to the corresponding author. Data will be shared in accordance with the Turkish Personal Data Protection Law (KVKK) and after approval of the proposal by the study investigators. A data sharing agreement may be required.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2025, 47 months.

Of 133 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 47 months is above that.

Counting every sponsor, half of 142 studies reached it within 11 months; a quarter within 3 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 18, 2026
StartActual
Jan 1, 2022
Primary completionActual
Dec 31, 2025
CompletionActual
Mar 1, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945262
Lead sponsor
Sakarya University
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 1, 2022
Primary completion
Dec 31, 2025
Completion
Mar 1, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion